- Home
- NN vs MESO Comparison
NN vs MESO Comparison
Compare NN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NN
- MESO
- Stock Information
- Founded
- NN 2007
- MESO 2004
- Country
- NN United States
- MESO Australia
- Employees
- NN N/A
- MESO N/A
- Industry
- NN Industrial Machinery/Components
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NN Industrials
- MESO Health Care
- Exchange
- NN Nasdaq
- MESO Nasdaq
- Market Cap
- NN 1.9B
- MESO 2.0B
- IPO Year
- NN N/A
- MESO N/A
- Fundamental
- Price
- NN $12.35
- MESO $14.56
- Analyst Decision
- NN
- MESO Buy
- Analyst Count
- NN 0
- MESO 2
- Target Price
- NN N/A
- MESO $24.00
- AVG Volume (30 Days)
- NN 1.4M
- MESO 188.9K
- Earning Date
- NN 11-06-2025
- MESO 08-28-2025
- Dividend Yield
- NN N/A
- MESO N/A
- EPS Growth
- NN N/A
- MESO N/A
- EPS
- NN N/A
- MESO N/A
- Revenue
- NN $5,539,000.00
- MESO $17,198,000.00
- Revenue This Year
- NN N/A
- MESO $440.77
- Revenue Next Year
- NN N/A
- MESO $110.74
- P/E Ratio
- NN N/A
- MESO N/A
- Revenue Growth
- NN 11.61
- MESO 191.39
- 52 Week Low
- NN $9.05
- MESO $8.52
- 52 Week High
- NN $18.54
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- NN 41.64
- MESO 32.59
- Support Level
- NN $11.34
- MESO $16.10
- Resistance Level
- NN $12.72
- MESO $16.91
- Average True Range (ATR)
- NN 0.77
- MESO 0.48
- MACD
- NN 0.01
- MESO -0.34
- Stochastic Oscillator
- NN 44.87
- MESO 6.77
About NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.